Literature DB >> 21691136

Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.

Mehmet Citirik1, Emrah Utku Kabatas, Cosar Batman, Kadir Okhan Akin, Naciye Kabatas.   

Abstract

PURPOSE: To assess vitreous vascular endothelial growth factor (VEGF) concentrations in proliferative diabetic retinopathy (PDR) in comparison to proliferative vitreoretinopathy (PVR). PATIENTS AND METHODS: Vitreous samples were collected from 69 eyes of 69 patients with traumatic lens dislocation (n = 10), grade B PVR with rhegmatogenous retinal detachment (n = 13), grade C PVR with rhegmatogenous retinal detachment (n = 14), PDR with vitreous hemorrhage (n = 18), and PDR with vitreous hemorrhage and tractional retinal detachment (n = 14). Vitreous fluid samples were obtained at vitrectomy, and the levels of VEGF were measured by enzyme-linked immunosorbent assay.
RESULTS: The mean vitreous level of VEGF was 15.14 ± 5.22 pg/ml in eyes with grade B PVR, 99.15 ± 38.58 pg/ml in eyes with grade C PVR, 4,534.01 ± 1,193.28 pg/ml in eyes with vitreous hemorrhage secondary to PDR, 5,157.29 ± 969.44 pg/ml in eyes with vitreous hemorrhage and tractional retinal detachment secondary to PDR, and 16.19 ± 5.76 pg/ml in eyes of the control group with traumatic lens dislocation. Vitreous VEGF concentrations were significantly higher in the patients with grade C PVR, PDR with vitreous hemorrhage and PDR with vitreous hemorrhage and tractional retinal detachment in comparison to the control patients (p < 0.05). A significant alteration was not observed in patients with grade B PVR (p = 0.55).
CONCLUSIONS: Vitreous VEGF concentrations are increased in PDR and grade C PVR. The high VEGF concentrations could suggest a possible effect of VEGF on advanced PVR.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691136     DOI: 10.1159/000324200

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  11 in total

1.  Translational vitreous proteomics.

Authors:  Vinit B Mahajan; Jessica M Skeie
Journal:  Proteomics Clin Appl       Date:  2013-11-04       Impact factor: 3.494

Review 2.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

3.  Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.

Authors:  K Ghasemi Falavarjani; M Hashemi; M Modarres; A Hadavand Khani
Journal:  Eye (Lond)       Date:  2014-02-21       Impact factor: 3.775

4.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

5.  Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle.

Authors:  Raluca Rusovici; Chirag J Patel; Kakarla V Chalam
Journal:  Clin Ophthalmol       Date:  2013-02-13

6.  Proteomic interactions in the mouse vitreous-retina complex.

Authors:  Jessica M Skeie; Vinit B Mahajan
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

7.  Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy.

Authors:  V V Chernykh; E V Varvarinsky; E V Smirnov; D V Chernykh; Alexander N Trunov
Journal:  Indian J Ophthalmol       Date:  2015-01       Impact factor: 1.848

Review 8.  Molecular Surgery: Proteomics of a Rare Genetic Disease Gives Insight into Common Causes of Blindness.

Authors:  Gabriel Velez; Vinit B Mahajan
Journal:  iScience       Date:  2020-10-13

9.  Intravitreal Injection of Bevacizumab in Primary Vitrectomy to Decrease the Rate of Retinal Redetachment: A Randomized Pilot Study.

Authors:  Adib Tousi; Hossein Hasanpour; Masoud Soheilian
Journal:  J Ophthalmic Vis Res       Date:  2016 Jul-Sep

10.  Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients.

Authors:  Teresa Tsai; Sandra Kuehn; Nikolaos Tsiampalis; Minh-Khoa Vu; Vinodh Kakkassery; Gesa Stute; H Burkhard Dick; Stephanie C Joachim
Journal:  PLoS One       Date:  2018-03-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.